Tigenix NV, a biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic stem cells, today announces that Eduardo Bravo will depart the board of directors and his role as CEO of Tigenix effective as of June 15, 2018.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Appointments_Eduardo-bravo.jpg580580h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-06-13 08:16:492018-06-13 08:16:49Tigenix announces change in Board of Directors
Celonic AG has pursued an ambitious expansion strategy in mammalian cell line contract manufacturing to establish Phase III and commercial supply by mid-2019. A new GMP facility in Heidelberg was acquired, and capacity is also being expanded at the headquarters in Basel. European Biotechnology spoke with Franzpeter Bracht, COO of Celonic, about Celonic’s strategy.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_online_background_celonicinterview.png456811Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-06-12 10:25:042024-04-02 16:21:20Expanding into the commercial supply space
Despite a 6-month improvement of 2-year-overall survival in pancreatic cancer patients, Norwegian cancer immunotherapy specialist Targovax ASA will terminate development of TG01 in this indication. Instead, development of RAS neoantigen-targeting cancer vaccines will be pushed in colorectal cancer.
Fibra-Cel Disks are an advanced, solid support material for the efficient growth of mammalian and insect cells in bioreactors. They are devised to improve the cultivation of anchorage-dependent as well as suspension cells. Fibra-Cel Disks can be used also for perfusion cell culture with the Eppendorf packed-bed impeller – available for glass, stainless steel, and single-use bioreactors.
British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price.
EU Commissioners Jyrki Katainen and Carlos Moedas proposed a budget increase of 25% for the next European Research and Innovation programme Horizon Europe (2021-27) vs Horizon 2020. However MEPs said that the new moonshot research section EIC is underfunded. Furthermore, the current funding quote of 11% was too low compared to other international excellence programmes.
https://european-biotechnology.com/wp-content/uploads/2024/04/EC_Horizon_Europe_P037339-40482.jpg12801920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-06-08 08:08:522018-06-08 08:08:52EC earmarks €100bn for Horizon Europe
Alkermes plc (Dublin) received a US$50m milestone payment from Biogen after review of preliminary Phase III gastrointestinal tolerability data of Alkermes’ relapsing-remitting multiple sclerosis candidate diroximel fumarate (BIIB098).
Austrian arenaviral vector technology specialist Hookipa Biotech AG (Vienna, Austria) has licenced its TheraT and Vaxwave technologies exclusively to Gilead Sciences Inc. to develop and globally commercialise vaccines against the human immunodeficiency virus (HIV) and the hepatitis B virus (HBV).
PureTech Health plc announced today that its affiliate, Gelesis, has appointed Harry Leider, MD, MBA, former Chief Medical Officer and Group Vice President of Walgreens, as Chief Medical Officer.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_online_Leiden.jpg303303h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-06-05 15:15:452018-06-05 15:15:45PureTech’s Gelesis Appoints Harry Leider as CMO
Tigenix announces change in Board of Directors
AppointmentsTigenix NV, a biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic stem cells, today announces that Eduardo Bravo will depart the board of directors and his role as CEO of Tigenix effective as of June 15, 2018.
Expanding into the commercial supply space
BackgroundCelonic AG has pursued an ambitious expansion strategy in mammalian cell line contract manufacturing to establish Phase III and commercial supply by mid-2019. A new GMP facility in Heidelberg was acquired, and capacity is also being expanded at the headquarters in Basel. European Biotechnology spoke with Franzpeter Bracht, COO of Celonic, about Celonic’s strategy.
Targovax refocussing clinical pipeline post-ASCO
Latest NewsDespite a 6-month improvement of 2-year-overall survival in pancreatic cancer patients, Norwegian cancer immunotherapy specialist Targovax ASA will terminate development of TG01 in this indication. Instead, development of RAS neoantigen-targeting cancer vaccines will be pushed in colorectal cancer.
Increase Your Culture Yields with Fibra-Cel® Disks
ProductsFibra-Cel Disks are an advanced, solid support material for the efficient growth of mammalian and insect cells in bioreactors. They are devised to improve the cultivation of anchorage-dependent as well as suspension cells. Fibra-Cel Disks can be used also for perfusion cell culture with the Eppendorf packed-bed impeller – available for glass, stainless steel, and single-use bioreactors.
Autolus Therapeutics aiming for NASDAQ IPO
Latest NewsBritish T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price.
EC earmarks €100bn for Horizon Europe
Latest NewsEU Commissioners Jyrki Katainen and Carlos Moedas proposed a budget increase of 25% for the next European Research and Innovation programme Horizon Europe (2021-27) vs Horizon 2020. However MEPs said that the new moonshot research section EIC is underfunded. Furthermore, the current funding quote of 11% was too low compared to other international excellence programmes.
Josh Muntner joins Mesoblast as CFO
AppointmentsJosh Muntner has been appointed Chief Financial Officer of Mesoblast. He will be based in New York.
MS: Alkermes bags US$50m milestone from Biogen
Latest NewsAlkermes plc (Dublin) received a US$50m milestone payment from Biogen after review of preliminary Phase III gastrointestinal tolerability data of Alkermes’ relapsing-remitting multiple sclerosis candidate diroximel fumarate (BIIB098).
Hookipa and Gilead ink US$400m deal
Latest NewsAustrian arenaviral vector technology specialist Hookipa Biotech AG (Vienna, Austria) has licenced its TheraT and Vaxwave technologies exclusively to Gilead Sciences Inc. to develop and globally commercialise vaccines against the human immunodeficiency virus (HIV) and the hepatitis B virus (HBV).
PureTech’s Gelesis Appoints Harry Leider as CMO
AppointmentsPureTech Health plc announced today that its affiliate, Gelesis, has appointed Harry Leider, MD, MBA, former Chief Medical Officer and Group Vice President of Walgreens, as Chief Medical Officer.